Idexx Laboratories (IDXX) Common Equity (2009 - 2026)

Idexx Laboratories (IDXX) has reported Common Equity for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 7.46% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 7.46% YoY), while the FY2025 annual figure was $1.6 billion, up 0.63% from the prior year.
• Common Equity came in at $1.6 billion for Q1 2026 at Idexx Laboratories, down from $1.6 billion in the prior quarter.
• The five-year high for Common Equity was $1.6 billion in Q3 2024, with the low at $457.0 million in Q2 2022.
• Average Common Equity over 5 years is $1.2 billion, with a median of $1.5 billion recorded in 2025.
• Across the five-year window, Common Equity sank 38.92% in 2022 and jumped 172.57% in 2023, its largest moves.
• Year by year, Common Equity stood at $608.7 million in 2022, then surged by 143.87% to $1.5 billion in 2023, then rose by 7.46% to $1.6 billion in 2024, then climbed by 0.63% to $1.6 billion in 2025, then decreased by 3.07% to $1.6 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $1.6 billion, $1.6 billion, and $1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.